Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) Research & Development: 2014-2025

Historic Research & Development for Ocugen (OCGN) over the last 11 years, with Sep 2025 value amounting to $11.1 million.

  • Ocugen's Research & Development rose 37.51% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 18.20%. This contributed to the annual value of $32.1 million for FY2024, which is 18.82% down from last year.
  • Ocugen's Research & Development amounted to $11.1 million in Q3 2025, which was up 32.69% from $8.4 million recorded in Q2 2025.
  • Ocugen's 5-year Research & Development high stood at $18.9 million for Q2 2021, and its period low was $2.9 million during Q1 2021.
  • Its 3-year average for Research & Development is $9.2 million, with a median of $8.4 million in 2025.
  • As far as peak fluctuations go, Ocugen's Research & Development skyrocketed by 1,056.63% in 2021, and later crashed by 60.71% in 2023.
  • Quarterly analysis of 5 years shows Ocugen's Research & Development stood at $7.1 million in 2021, then spiked by 142.57% to $17.2 million in 2022, then slumped by 54.84% to $7.8 million in 2023, then increased by 6.57% to $8.3 million in 2024, then surged by 37.51% to $11.1 million in 2025.
  • Its Research & Development stands at $11.1 million for Q3 2025, versus $8.4 million for Q2 2025 and $9.5 million for Q1 2025.